Vernalis (LON:VER) - Worth the wait

Friday, Feb 24 2012 by

Feb 24th 2012 - Edison Investment Research today published a report on Vernalis (VER.L, LSE:VER, LON:VER) entitled "Worth The Wait". In summary, the report says:

Vernalis’s proposed £65.9m equity raise (net of costs) and multi-product in-licensing deal with private US company Tris Pharma are the latest steps in its business transformation strategy. While the company has made progress in its clinical pipeline and in balancing investment in research, pipeline expansion through M&A was always the most important facet of its three-part strategy to become a diversified, profitable and sustainable specialty pharma company. The scope of the Tris deal and the size of the addressable market means that Vernalis is a step closer to this goal.




About Edison Investment Research

Edison Investment Research

Follow

Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals work with leading companies, fund managers and investment banks worldwide to support their capital markets activity.  We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington.  Edison is authorised and regulated by the Financial Conduct Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »